Dewpoint Therapeutics and Bayer are to collaborate on research into new treatments in gynaecology and cardiology, capitalising on Bayer’s small molecule compound library and Dewpoint’s proprietary platform for biomolecular condensates.
Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development, Dr. Joerg Moeller, said: "As we continue to broaden our capabilities in Research and Development, the collaboration with Dewpoint gives us access to breakthrough innovation potential. New analytic tools and a growing understanding of biomolecular condensates could provide new insights into cellular functions that previously have not been considered by scientists in drug development, enabling us to identify novel pharmacological targets for future therapies."
“Dewpoint Therapeutics and Bayer agree collaboration.“
Amir Nashat, Dewpoint’s chief executive officer, said: "This partnership is an exciting opportunity to advance treatments for diseases that have long evaded the industry. We look forward to combining Bayer's expertise in chemistry and drug development and Dewpoint's novel platform and insights into the role of biomolecular condensates in disease. We also look forward to working closely with Bayer to expand our capabilities in Germany and put the local biotech ecosystem at the forefront of this important and emerging area."